Biotech · Private company
Melinta Therapeutics, Inc.
Track this companyFree. Adds Melinta Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials131 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- DelafloxacinPhase 3 · Community Acquired Bacterial PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- IV VancomycinPhase 3 · Wound InfectionClinicalTrials.gov · fetched Nov 12, 2026
- LinezolidPhase 3 · Community Acquired Bacterial PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- MoxifloxacinPhase 3 · Community Acquired Bacterial PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- Single-Dose IV Oritavancin DiphosphatePhase 3 · Wound InfectionClinicalTrials.gov · fetched Nov 12, 2026
- SolithromycinPhase 3 · Community-acquired Bacterial PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- DelafloxacinPhase 2 · Skin and Subcutaneous Tissue Bacterial InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- KimyrsaPhase 2 · Acute Bacterial Skin and Skin Structure InfectionClinicalTrials.gov · fetched Nov 12, 2026
- LinezolidPhase 2 · Skin and Subcutaneous Tissue Bacterial InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- OrbactivPhase 2 · Acute Bacterial Skin and Skin Structure InfectionClinicalTrials.gov · fetched Nov 12, 2026
- VancomycinPhase 2 · Skin and Subcutaneous Tissue Bacterial InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Current Formulation of OritavancinPhase 1 · Acute Bacterial Skin and Skin Structure InfectionClinicalTrials.gov · fetched Nov 12, 2026
- MoxifloxacinPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- OritavancinPhase 1 · Gram-positive Bacterial InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- OritavancinPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Single-Dose IV Oritavancin DiphosphatePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Single-Dose IV Oritavancin Diphosphate and WarfarinPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dosePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- Rezafungin Prophylaxis in Liver TransplantPHASE3 · ENROLLING_BY_INVITATION · started Oct 15, 2025ClinicalTrials.gov NCT06774144 · fetched Nov 12, 2026
- Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin InfectionsPHASE2 · COMPLETED · started Jun 15, 2023ClinicalTrials.gov NCT05599295 · fetched Nov 12, 2026
- Relative Exposure and Safety Study of Kimyrsa in ABSSSI PatientsPHASE1 · COMPLETED · started Jul 16, 2019ClinicalTrials.gov NCT03873987 · fetched Nov 12, 2026
- Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial PneumoniaPHASE3 · COMPLETED · started Dec 14, 2016ClinicalTrials.gov NCT02679573 · fetched Nov 12, 2026
- Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial PneumoniaPHASE2_PHASE3 · TERMINATED · started Apr 1, 2016ClinicalTrials.gov NCT02605122 · fetched Nov 12, 2026
- Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy SubjectsPHASE1 · COMPLETED · started Jun 1, 2015ClinicalTrials.gov NCT02470702 · fetched Nov 12, 2026
- Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy SubjectsPHASE1 · COMPLETED · started Apr 1, 2015ClinicalTrials.gov NCT02340988 · fetched Nov 12, 2026
- Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial InfectionsPHASE1 · COMPLETED · started May 1, 2014ClinicalTrials.gov NCT02134301 · fetched Nov 12, 2026
- Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy VolunteersPHASE1 · COMPLETED · started Jan 1, 2013ClinicalTrials.gov NCT01784536 · fetched Nov 12, 2026
- A Study to Assess the Cardiac Safety of Oritavancin in Healthy ParticipantsPHASE1 · COMPLETED · started Dec 27, 2012ClinicalTrials.gov NCT01762839 · fetched Nov 12, 2026
- A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin InfectionsPHASE2 · COMPLETED · started Jan 1, 2011ClinicalTrials.gov NCT01283581 · fetched Nov 12, 2026
- Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)PHASE3 · COMPLETED · started Dec 1, 2010ClinicalTrials.gov NCT01252719 · fetched Nov 12, 2026
- Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionPHASE3 · COMPLETED · started Dec 1, 2010ClinicalTrials.gov NCT01252732 · fetched Nov 12, 2026